M. Drulak

发表

A Phenotype–Genotype Approach to Predicting CYP450 and P‐Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir

M. Wagner, T. Macgregor, M. Vourvahis, 2010, Clinical pharmacology and therapeutics.

Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.

R. Sekulovich, S. Winston, R. Burke, 2000, Viral immunology.

Comparative in vitro activity of ceftizoxime, cefoperazone, and cefoxitin against anaerobic bacteria

A. Chow, M. Drulak, 1981, Antimicrobial Agents and Chemotherapy.

Evaluation of the modified Visuwell Strep-A enzyme immunoassay for detection of group-A Streptococcus from throat swabs.

S. Winston, D. Amsterdam, W. Bartholomew, 1991, Diagnostic microbiology and infectious disease.

TRANxITION 144‐week results: switching virologically stable HIV patients from immediate‐release nevirapine (NVP IR) to extended‐release NVP (XR)

D. Ward, K. Arastéh, M. Drulak, 2012 .

VERxVE 144 week results: nevirapine extended‐release (NVP XR) QD versus NVP immediate‐release (IR) BID with FTC/TDF in treatment‐naïve HIV‐1 patients

D. Podzamczer, J. Bogner, M. Nelson, 2012 .

Efficacy and Safety of Nevirapine Extended-Release Once Daily versus Nevirapine Immediate-Release Twice-Daily in Treatment-Naive HIV-1-Infected Patients

D. Podzamczer, P. Cahn, A. Horban, 2011, Antiviral therapy.

The relative effectiveness of commonly used disinfectants in inactivation of echovirus 11

M. Drulak, A. Wallbank, I. Lebtag, 1978, Journal of Hygiene.

The relative resistance of f2 bacteriophage to inactivation by disinfectants

M. Drulak, A. Wallbank, I. Lebtag, 1979, Journal of Hygiene.

The relative effectiveness of commonly used disinfectants in inactivation of coxsackievirus B5

M. Drulak, L. Poffenroth, A. Wallbank, 1978, Journal of Hygiene.

Wescodyne: lack of activity against poliovirus in the presence of organic matter.

M. Drulak, L. Poffenroth, A. Wallbank, 1978, Health laboratory science.

Anti-immunoglobulin analysis by diffusion patterns of inhibition and facilitation of complementary lysis in agar. II. Diffusion-lysis as a method for recognizing in vivo immunosuppressive activity of anti-immunoglobulins.

M. Drulak, J. Romeyn, J. Cook, 1975, Journal of immunological methods.

Comparison of Visuwell enzyme immunoassay to culture for detection of group A Streptococcus in throat swab specimens.

S. Winston, J. Yong, M. Drulak, 1988, Diagnostic microbiology and infectious disease.

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

D. Podzamczer, J. Mallolas, C. Orrell, 2017, HIV clinical trials.